Q3 2024 |
827 |
$977M |
+$211M |
-$150M |
+$60.2M |
SMCI, IBD, CAT, USFR, ISRG
|
13F-HR |
10/10/2024, 03:44 PM |
Q2 2024 |
802 |
$868M |
+$93.5M |
-$171M |
-$77.6M |
IBD, USFR, CAT, ISRG, WWJD
|
13F-HR |
8/12/2024, 05:01 PM |
Q1 2024 |
792 |
$977M |
+$176M |
-$175M |
+$1.57M |
CAT, USFR, ISRG, IBD, PGR
|
13F-HR |
5/7/2024, 04:51 PM |
Q4 2023 |
785 |
$909M |
+$128M |
-$87.6M |
+$40.4M |
IBD, USFR, CAT, NOW, WWJD
|
13F-HR |
2/12/2024, 02:43 PM |
Q3 2023 |
791 |
$783M |
+$148M |
-$156M |
-$8.53M |
IBD, USFR, CAT, NOW, PLD
|
13F-HR |
10/26/2023, 11:59 AM |
Q2 2023 |
788 |
$827M |
+$130M |
-$120M |
+$10.2M |
IBD, USFR, ISRG, PLD, NOW
|
13F-HR |
7/31/2023, 10:23 AM |
Q1 2023 |
782 |
$786M |
+$116M |
-$142M |
-$25.9M |
USFR, IBD, PLD, ADI, NOW
|
13F-HR |
4/24/2023, 10:24 AM |
Q4 2022 |
743 |
$777M |
+$82.9M |
-$61.5M |
+$21.5M |
TFLO, USFR, IBD, WWJD, BLES
|
13F-HR |
1/26/2023, 02:28 PM |
Q3 2022 |
754 |
$708M |
+$138M |
-$155M |
-$17.5M |
TFLO, USFR, IBD, UUP, WWJD
|
13F-HR |
11/7/2022, 05:01 PM |
Q2 2022 |
762 |
$754M |
+$171M |
-$155M |
+$15.9M |
USFR, IBD, UUP, WWJD, BLES
|
13F-HR |
8/10/2022, 12:37 PM |
Q1 2022 |
788 |
$864M |
+$155M |
-$102M |
+$52.6M |
VGSH, IBD, PHYS, BLES, WWJD
|
13F-HR |
4/21/2022, 10:10 AM |
Q4 2021 |
786 |
$872M |
+$121M |
-$78.6M |
+$42.3M |
IBD, VGLT, ISRG, NOW, PLD
|
Restatement |
2/14/2022, 10:02 AM |
Q3 2021 |
794 |
$791M |
+$422M |
-$359M |
+$63.5M |
IBD, VGLT, ISRG, NOW, BLES
|
13F-HR |
11/9/2021, 02:02 PM |
Q2 2021 |
593 |
$760M |
+$113M |
-$48.6M |
+$64.7M |
NVDA, IBD, BLES, VGLT, ISMD
|
13F-HR |
8/10/2021, 04:58 PM |
Q1 2021 |
597 |
$652M |
+$237M |
-$75.9M |
+$161M |
NVDA, IBD, VGIT, BLES, ISMD
|
13F-HR |
4/30/2021, 12:07 PM |
Q4 2020 |
622 |
$452M |
+$140M |
-$98.9M |
+$41.1M |
IBD, BLES, NVDA, ISMD, WWJD
|
13F-HR |
2/12/2021, 02:47 PM |
Q3 2020 |
432 |
$363M |
+$119M |
-$60.6M |
+$58.6M |
VGIT, IBD, BLES, NVDA, WWJD
|
13F-HR |
11/16/2020, 04:27 PM |
Q2 2020 |
485 |
$290M |
+$60.3M |
-$64.6M |
-$4.29M |
IBD, BLES, WWJD, ISMD, BIBL
|
13F-HR |
8/12/2020, 03:46 PM |
Q1 2020 |
739 |
$250M |
+$76.4M |
-$43.1M |
+$33.4M |
IBD, BLES, WWJD, ISMD, BIBL
|
13F-HR |
5/8/2020, 04:44 PM |
Q4 2019 |
351 |
$279M |
+$20.3M |
-$22.3M |
-$1.94M |
IBD, BLES, ISMD, BIBL, WWJD
|
13F-HR |
1/24/2020, 12:28 PM |
Q3 2019 |
375 |
$262M |
+$38.7M |
-$13.4M |
+$25.3M |
IBD, BLES, ISMD, BIBL, UNP
|
13F-HR |
11/13/2019, 02:18 PM |
Q2 2019 |
328 |
$238M |
+$30M |
-$10.2M |
+$19.8M |
IBD, BLES, ISMD, BIBL, UNP
|
13F-HR |
7/16/2019, 01:32 PM |
Q1 2019 |
297 |
$215M |
+$56M |
-$9.26M |
+$46.7M |
IBD, BLES, ISMD, BIBL, ABBV
|
13F-HR |
5/16/2019, 07:42 AM |
Q4 2018 |
242 |
$149M |
+$14M |
-$4.66M |
+$9.32M |
BLES, IBD, ISMD, BIBL, ABBV
|
Restatement |
2/21/2019, 06:01 PM |
Q3 2018 |
237 |
$162M |
+$20.8M |
-$3.87M |
+$16.9M |
BLES, IBD, ISMD, BIBL, NVDA
|
Restatement |
2/21/2019, 05:59 PM |
Q2 2018 |
220 |
$141M |
+$42.1M |
-$1.57M |
+$40.5M |
BLES, IBD, ISMD, BIBL, ABBV
|
Restatement |
2/21/2019, 05:59 PM |
Q1 2018 |
199 |
$98.2M |
+$17.4M |
-$35.6M |
-$18.2M |
BLES, IBD, ISMD, BIBL, ITW
|
Restatement |
2/21/2019, 09:04 PM |
Q4 2017 |
913 |
$118M |
$0 |
$0 |
|
BLES, IBD, ISMD, BIBL, NUE
|
Restatement |
2/21/2019, 05:49 PM |